The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to investigate the influence of gonadotropin releasing hormone agonist (GnRHa) treatment on the weight and body mass index (BMI) of girls who were diagnosed with idiopathic central precocious puberty (CPP) or early puberty (EP). Methods: Patients who were younger than 8 years of age at diagnosis were classified as CPP and patients aged between 8 and 9 years at diagnosis were classified as EP. Of 129 patients, 34 were diagnosed with CPP and 95 were diagnosed with EP. The patients were divided according to pretreatment weight status into normal weight group, an overweight group, or an obese group. Results: No significant changes were observed with respect to the weight standard deviation score (SDS) before and after 1 year, 2 years of treatment, respectively (P>0.05, P>0.05) in all patient groups. No significant changes were observed in relation to the BMI SDS before and after 1 year, 2 years of treatment, respectively (P>0.05, P>0.05) in all patient group. Depending on the degree of obesity, differences with respect to the weight SDS and BMI SDS were observed. Conclusion: BMI SDS increased in the GnRHa-treated patients as a whole group, but was not statistically significant. But BMI SDS increased significantly in the normal weight group after 2 years of GnRHa treatment. So, GnRHa treatment may affect the change of BMI SDS depending on degree of obesity.
Abstract
Purpose: This study aimed to investigate the influence of gonadotropin releasing hormone agonist (GnRHa) treatment on the weight and body mass index (BMI) of girls who were diagnosed with idiopathic central precocious puberty (CPP) or early puberty (EP). Methods: Patients who were younger than 8 years of age at diagnosis were classified as CPP and patients aged between 8 and 9 years at diagnosis were classified as EP. Of 129 patients, 34 were diagnosed with CPP and 95 were diagnosed with EP. The patients were divided according to pretreatment weight status into normal weight group, an overweight group, or an obese group. Results: No significant changes were observed with respect to the weight standard deviation score (SDS) before and after 1 year, 2 years of treatment, respectively (P>0.05, P>0.05) in all patient groups. No significant changes were observed in relation to the BMI SDS before and after 1 year, 2 years of treatment, respectively (P>0.05, P>0.05) in all patient group. Depending on the degree of obesity, differences with respect to the weight SDS and BMI SDS were observed. Conclusion: BMI SDS increased in the GnRHa-treated patients as a whole group, but was not statistically significant. But BMI SDS increased significantly in the normal weight group after 2 years of GnRHa treatment. So, GnRHa treatment may affect the change of BMI SDS depending on degree of obesity.
참고문헌 (31)
- Parent AS, "The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration", Endocr Rev, 24, pp.668~693 (2003)
- Lee PA, "Central precocious puberty. An overview of diagnosis, treatment, and outcome", Endocrinol Metab Clin North Am, 28, pp.901~918 (1999)
- Pescovitz OH, "Premature thelarche and central precocious puberty: the relationship between clinical presentation and the gonadotropin response to luteinizing hormone-releasing hormone", J Clin Endocrinol Metab, 67, pp.474~479 (1988)
- Carel JC, "Clinical practice. Precocious puberty", N Engl J Med, 358, pp.2366~2377 (2008)
- Feuillan PP, "Reproductive axis after discontinuation of gonadotropinreleasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty", J Clin Endocrinol Metab, 84, pp.44~49 (1999)
- 이승재, "Effects of Gonadotropin-Releasing Hormone Agonist Therapy on Body Mass Index and Height in Girls with Central Precocious Puberty", 전남의대학술지, 48(1), pp.27~31 (2012), 의과학연구소
- Chiumello G, "Precocious puberty and body composition: effects of GnRH analog treatment", J Pediatr Endocrinol Metab, 13(Suppl 1), pp.791~794 (2000)
- Carel JC, "Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty", J Clin Endocrinol Metab, 84, pp.1973~1978 (1999)
- Oostdijk W, "Final height in central precocious puberty after long term treatment with a slow release GnRH agonist", Arch Dis Child, 75, pp.292~297 (1996)
- Boot AM, "Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty", J Clin Endocrinol Metab, 83, pp.370~373 (1998)
- Heger S, "Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function", J Clin Endocrinol Metab, 84, pp.4583~4590 (1999)
- Głab E, "Influence of GnRH analog therapy on body mass in central precocious puberty", Pediatr Endocrinol Diabetes Metab, 15, pp.7~11 (2009)
- Palmert MR, "Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty", J Clin Endocrinol Metab, 84, pp.4480~4488 (1999)
- Messaaoui A, "Treatment of central precocious puberty with Gonadotropin- Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment", Rev Med Brux, 26, pp.27~32 (2005)
- Arrigo T, "Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty", Eur J Endocrinol, 150, pp.533~537 (2004)
- van der Sluis IM, "Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy", J Clin Endocrinol Metab, 87, pp.506~512 (2002)
- 문진수, "2007 한국 소아 청소년 성장도표 : 개발 과정과 전망", Korean Journal of Pediatrics, 51(1), pp.1~25 (2008), 대한소아과학회
- Greulich WW, "Radiologic atlas of skeletal development of the hand and wrist" (1959), Stanford University Press
- Marshall WA, "Variations in pattern of pubertal changes in girls", Arch Dis Child, 44, pp.291~303 (1969)
- Tanner JM, "Standards for children's height at ages 2-9 years allowing for heights of parents", Arch Dis Child, 45, pp.755~762 (1970)
- 오경원, "한국 소아청소년의 비만 유병률 추이: 1997년과 2005년 비교", Korean Journal of Pediatrics, 51(9), pp.950~955 (2008), 대한소아과학회
- 이미화, "한국 청소년 여성에서의 비정상 사춘기 발달", Obstetrics & Gynecology Science, 52(12), pp.1197~1203 (2009), 대한산부인과학회
- Magiakou MA, "The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study", J Clin Endocrinol Metab, 95, pp.109~117 (2010)
- Kaplowitz PB, "Earlier onset of puberty in girls: relation to increased body mass index and race", Pediatrics, 108, pp.347~353 (2001)
- Rosenfield RL, "Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index", Pediatrics, 123, pp.84~88 (2009)
- Shiasi Arani K, "Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls", Int J Endocrinol Metab, 13, pp.e23085~ (2015)
- Ko JH, "Changes in bone mineral density and body composition in children with central precocious puberty and early puberty before and after one year of treatment with GnRH agonist", Horm Res Paediatr, 75, pp.174~179 (2011)
- Wolters B, "Treatment with gonadotropinreleasing hormone analogues: different impact on body weight in normal-weight and overweight children", Horm Res Paediatr, 78, pp.304~311 (2012)
- Lazar L, "Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades", J Clin Endocrinol Metab, 100, pp.1445~1451 (2015)
- Pasquino AM, "Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropinreleasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function", J Clin Endocrinol Metab, 93, pp.190~195 (2008)
- Colmenares A, "Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment", Int J Pediatr Endocrinol, 2014, pp.5~ (2014)